Related Experiment Video
Updated: Aug 14, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy
1Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, Colorado 80309 USA.
Insights
Three myosin mutations causing familial hypertrophic cardiomyopathy show impaired ATPase activity. The severity of this enzymatic defect in mutant myosins correlates with patient clinical outcomes.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Familial hypertrophic cardiomyopathy (HCM) is a genetic heart disease often caused by mutations in myosin heavy chain.
- Understanding the biochemical basis of HCM is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the functional impact of three specific myosin heavy chain mutations associated with HCM.
- To determine if the biochemical defects in mutant myosins correlate with the clinical severity in patients.
Main Methods:
- Expressed histidine-tagged rat cardiac myosin motor domains with ventricular light chain 1 in mammalian COS cells.
- Studied wild-type alpha-cardiac myosin and three specific mutations (Arg249Gln, Arg403Gln, Val606Met).
- Assessed actin-activated ATPase activities of wild-type and mutant myosins.
Main Results:
- Expressed myosin motor domains exhibited physiological ATPase properties.
- All three myosin mutants displayed defects in ATPase activity.
- The degree of enzymatic impairment correlated with the clinical phenotype severity in patients.
Conclusions:
- Rodent alpha-cardiac myosin models are relevant for studying human HCM biochemical mechanisms.
- Biochemical defects in myosin motor function are directly linked to the clinical presentation of familial hypertrophic cardiomyopathy.
Abstract:
We have studied the actin-activated ATPase activities of three mutations in the motor domain of the myosin heavy chain that cause familial hypertrophic cardiomyopathy. We placed these mutations in rodent alpha-cardiac myosin to establish the relevance of using rodent systems for studying the biochemical mechanisms of the human disease. We also wished to determine whether the biochemical defects in these mutant alleles correlate with the severity of the clinical phenotype of patients with these alleles. We expressed histidine-tagged rat cardiac myosin motor domains along with rat ventricular light chain 1 in mammalian COS cells. Those myosins studied were wild-type alpha-cardiac and three mutations in the alpha-cardiac myosin heavy chain head (Arg249Gln, Arg403Gln, and Val606Met). These mutations in human beta-cardiac myosin heavy chain have predominantly moderate, severe, and mild clinical phenotypes, respectively. The crystal structure of the skeletal myosin head shows that the Arg249Gln mutation is near the ATP-binding site and the Arg403Gln and Val606Met mutations are in the actin-binding region. Expressed histidine-tagged alpha-motor domains retain physiological ATPase properties similar to those derived from cardiac tissue. All three myosin mutants show defects in the ATPase activity, with the degree of enzymatic impairment of the mutant myosins correlated with the clinical phenotype of patients with the disease caused by the corresponding mutation.
Related Concept Videos
Overview of Myosin Structure and Function
ATP Synthase: Mechanism
The Sarcomere
Each myosin...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy

